Belgium, Mont Saint-Guibert, April 10 – Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echoâ„¢-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases. Natural Killer (NK) cells are increasingly leveraged in these therapies for their ability to destroy harmful cancerous cells in their early stages, making them a promising option for the treatment of blood cancers, solid tumors, and autoimmune diseases. Cellistic’s Echoâ„¢-NK platform provides drug developers with a commercially viable solution for an Off-the-Shelf NK cell therapy. [Read more…]
Sernova Advances Cell Pouch Type I Diabetes Trial; Will Test iPSC-Derived Clusters Next
-
Current Trial (Cohorts A–C): Sernova’s current cohorts are focused on testing the safety and tolerability of transplanting donor islets (from cadaveric pancreases) into Sernova’s Cell Pouch device in T1D patients.
-
Future Direction (Post-Cohort C): Next, Sernova plans to launch a new clinical trial using iPSC-derived islet-like clusters, instead of relying on donor islets. This will be in collaboration with Evotec, a leading iPSC company.
-
Why iPSCs Matter: iPSC-derived islet-like clusters offer a renewable, potentially unlimited cell source for treating T1D, overcoming the limitations of donor availability. This aligns with Sernova’s goal of developing a scalable and widely accessible solution.
Cellino and Matricelf Collaborate to Scale iPSC-Derived Treatments for Spinal Cord Injury (SCI)
Cellino successfully manufactures and delivers autologous iPSC lines from four donors to Matricelf for groundbreaking neural tissue engineering.
Matricelf transformed Cellino-generated iPSCs into functional neural tissues with synchronized electrical activity.
CAMBRIDGE, Mass. – Cellino and Matricelf (TASE: MTLF) announced a collaboration to accelerate the global biomanufacturing of personalized spinal cord injury treatments using Cellino’s Nebulaâ„¢ technology combined with Matricelf’s breakthrough regenerative approach. This collaboration combines Cellino’s automated iPSC manufacturing with Matricelf’s double autologous 3D differentiation process, paving the way for scalable, patient-specific regenerative therapies. [Read more…]
Garuda Therapeutics Closes $50 Million Series A-1 Financing to Advance Off-the-Shelf Blood Stem Cell Therapies
New funding will accelerate Garuda’s rapid growth and fund development of off-the-shelf hematopoietic stem cell (HSC) therapies for a multitude of severe and life-threatening diseases
CAMBRIDGE, Mass., March 04, 2025 — Garuda Therapeutics (Garuda), a biotechnology company creating off-the-shelf, HSC therapies for a multitude of blood disorders, today announced the successful completion of an approximately $50 million Series A-1 funding round. Investors included OrbiMed, Northpond Ventures and Cormorant Asset Management, with new strategic investment from Kyowa Kirin Co., Ltd., a Japan-based Global Specialty Pharmaceutical Company. [Read more…]
Coeptis Therapeutics to Pursue Phase 2 Program Using Allogeneic Cord-Blood Derived NK Cell Therapy
Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and death
DVX201 is the world’s first-ever allogeneic, cord-blood derived NK cell therapy generated from pooled donor CD34+ hematopoietic stem and progenitor cells (HSPC) cells.
WEXFORD, PA, Feb 7, 2024 — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer and infectious diseases, announced plans to pursue DVX201, its proprietary allogeneic stem cell expansion and directed differentiation platform of unmodified natural killer (NK) cell therapy, as an antiviral treatment addressing various respiratory viral infections that lead to hospitalization, including the “tripledemic” of influenza, COVID-19 and respiratory syncytial virus (RSV). [Read more…]
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 117
- Next Page »




